You just read:

Lenvatinib Demonstrates Positive Results vs Sorafenib Across All Endpoints in First-Line Phase 3 Non-inferiority Trial of Unresectable Hepatocellular Carcinoma (uHCC)

News provided by

Eisai Inc.

Jun 04, 2017, 08:30 ET